Half-Year Tally in Clinical Diagnostics
Executive Summary
The top seven IVD manufacturers had lackluster 4% growth (in local currency) during the first half of 2003, compared to the same period in 2002, but the weaknesses were not evenly distributed. Perhaps the largest story in diagnostics these days is the surprising deterioration of the self-glucose testing market, one of the largest and most profitable sectors of the industry, and until recently, its biggest driver of growth.
You may also be interested in...
Two Rising Stars in Glucose Testing
Despite its attraction, diabetes glucose monitoring remains a tough field for newcomers, who face competition from four major-league, entrenched players. But two of the newer entrants appear to be succeeding--not because of revolutionary technology, but because of partnering savvy, efficient execution, and technological competence. Analysts expect Inverness Medical's symbiotic relationship with LifeScan to help Inverness's diabetes sales grow 30% a year as LifeScan pushes Inverness-made products as a major part of its fight to regain its market leadership. Home Diagnostics Inc.'s success with co-branding raises the prospect that discounting, until now not a significant factor, will become much more common in the field.
Washington State To Restrict Phthalates In Fragrance; Alternatives ‘Feasible And Available’
Personal-care and beauty products can do without fragrances that contain phthalates, says Washington Department of Ecology in a November Draft Regulatory Determinations Report to state lawmakers as per the Safer Products for Washington Act. Restriction specifics will be worked out in 2022 in consultation with stakeholders, Ecology says.
Drug Pricing Day At The US Supreme Court
Case before high court involving Medicare payment to hospitals for discounted outpatient drugs does not directly involve manufacturers. But the scope of the ruling could have a profound effect on how much leeway the government has to address drug pricing using administrative tools.